Precision, quantitative brain imaging analysis
iQ-solutionTM monitors brain disease with submillimeter precision, heralding a new era in quantitative magnetic resonance image analysis
SNAC’s iQ (intelligent quantification) product series provides robust, quantitative analysis of brain structures from MRI images, delivering personalized monitoring and precision management for patients with chronic neurological diseases. With iQ solutions, both radiologists and physicians can accurately assess changes in a patient’s brain structure in real time. For example, changes in the volume and location of ‘lesions’ in multiple sclerosis and cerebrovascular disease; and regional brain volume changes in Alzheimer dementia and other neurodegenerative diseases can be rapidly assessed, guiding management strategy and proving a quantitative evaluation of treatment response.
Sydney Neuroimaging Analysis Center (SNAC) has been an extraordinary partner in our clinical plans for our lead asset. When we considered Australia for our clinical trial work in neurodegenerative disease, it was quickly apparent that SNAC was the right partner. We’ve been incredibly grateful for the support we’ve received from every team member at SNAC; the SNAC team members consistently provide a level of professionalism and solid collaboration in the rigorous clinical framework required for pharmaceutical clinical drug development. Clene looks forward to further partnership with SNAC.
— Rob Etherington , President & CEO , Clene Nanomedicine